Shares of Intellia Therapeutics (NASDAQ:NTLA) surged 8.06% in premarket trading on Thursday as the gene-editing company reported better-than-expected fourth-quarter results and provided updates on the robust progress across its pipeline candidates.

For the fourth quarter, Intellia reported a narrower-than-expected loss of $1.27 per share, beating analysts' estimate of a $1.36 loss. Collaboration revenue also exceeded expectations, coming in at $12.9 million, compared to the consensus estimate of $8.53 million.

More importantly, Intellia provided promising updates on its key pipeline programs, including NTLA-2002 for hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) for transthyretin (ATTR) amyloidosis. The company dosed the first patient in the global Phase 3 HAELO study for NTLA-2002, with plans to complete enrollment in the second half of 2025 and submit a Biologics License Application in the second half of 2026 for a potential U.S. launch in 2027. Meanwhile, enrollment in the pivotal Phase 3 MAGNITUDE trial for nex-z in ATTR amyloidosis with cardiomyopathy is tracking ahead of projections, with over 550 total patients expected to be enrolled by year-end.